Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
December 15 2021 - 8:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced that it
entered into a lease agreement to expand its headquarters in South
San Francisco, California. The lease is expected to commence on
April 1, 2022, and the additional 47,566 square feet of office and
laboratory space will support the growth of its research platform
and correlative clinical development activities.
“Our team, our research capabilities, and our drive for
innovation continue to grow,” said David Chang, M.D., Ph.D.,
President, Chief Executive Officer and Co-Founder of Allogene. “As
we look into 2022 and beyond, this additional space will allow us
to advance our broad pipeline of AlloCAR T therapies aimed at
expanding the reach of cell therapy to more patients with
hematologic cancers and solid tumors.”
With this lease the company will occupy over 100,000 square feet
at its headquarters in South San Francisco. In addition, Allogene
has built Cell Forge 1, a state-of-the-art cell therapy
manufacturing facility in Newark, CA.
Allogene was represented by CBRE Inc. in this transaction.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) therapies for cancer. Led by a management team with
significant experience in cell therapy, Allogene is developing
a pipeline of “off-the-shelf” CAR T cell therapy candidates
with the goal of delivering readily available cell therapy
on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com,
and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to progress the ALPHA2
trial of ALLO-501A and proceed to the Phase 2 portion of the trial;
the ability to resolve the current clinical hold on the Company’s
trials; the ability to manufacture AlloCAR T therapy; the ability
to develop allogeneic CAR T therapies for cancer and the potential
benefits of AlloCAR T therapy. Various factors may cause
differences between Allogene’s expectations and actual results as
discussed in greater detail in Allogene’s filings with the SEC,
including without limitation in its Form 10-Q for the quarter ended
September 30, 2021. Any forward-looking statements that are made in
this press release speak only as of the date of this press release.
Allogene assumes no obligation to update the forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Sep 2023 to Sep 2024